Abstract
Purpose: The T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign was previously reported as a diagnostic indicator of diffuse astrocytoma, isocitrate dehydrogenase-mutant, and 1p/19q noncodeletion. Subsequently, it was reported that the same findings were observed in diffuse intrinsic pontine glioma (DIPG). We investigated the clinical significance of T2-FLAIR mismatch sign in DIPG. Methods: Twenty-one patients with DIPG (Male: Female = 12:9) were treated at our institute between 2004 and 2019. All patients were treated with local radiotherapy of 54 Gy/30 fractions. The positive T2-FLAIR mismatch sign was defined if it fulfilled the following criteria: (1) T2-FLAIR mismatch volume was >50% of T2 high volume at nonenhanced area, (2) the FLAIR low lesion is not associated with gadolinium enhancement (inside of enhancement or just outside of enhancement defined as edema), and (3) signal-intensity of FLAIR lowest lesion at tumor is lower than the normal cerebellar cortex. Results: In our patient series, T2-FLAIR mismatch sign was found in 5 out of 21 patients. Objective response rate of radiotherapy was 100% in patients positive for T2-FLAIR mismatch, while it was 25.0% in patients negative for T2-FLAIR mismatch, and this difference was statistically significant (p < 0.01, Fisher’s exact test). In patients under the age of 18-years, T2-FLAIR mismatch positive had a slightly better prognosis (p < 0.05, Wilcoxon test). Conclusion: T2-FLAIR mismatch sign in DIPG may be an indicator for better response to radiotherapy and a better prognostic factor.
Journal Section:
Editor's choice
References
1.
Rechberger
JS
, Lu
VM
, Zhang
L
, Power
EA
, Daniels
DJ
. Clinical trials for diffuse intrinsic pontine glioma: the current state of affairs
. Childs Nerv Syst
. 2020
;36
(1
):39
–46
.2.
Pollack
IF
, Agnihotri
S
, Broniscer
A
. Childhood brain tumors: current management, biological insights, and future directions
. J Neurosurg Pediatr
. 2019 Mar 1
;23
(3
):261
–73
.3.
El-Khouly
FE
, Veldhuijzen van Zanten
SEM
, Santa-Maria Lopez
V
, Hendrikse
NH
, Kaspers
GJL
, Loizos
G
, . Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand
. J Neurooncol
. 2019 Oct
;145
(1
):177
–84
.4.
Rashed
WM
, Maher
E
, Adel
M
, Saber
O
, Zaghloul
MS
. Pediatric diffuse intrinsic pontine glioma: where do we stand
. Cancer Metastasis Rev
. 2019 Dec 4
;38
(4
):759
–70
.5.
Hoffman
LM
, Veldhuijzen van Zanten
SEM
, Colditz
N
, Baugh
J
, Chaney
B
, Hoffmann
M
, . Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of Diffuse Intrinsic Pontine Glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries
. J Clin Oncol
. 2018 Jul 1
;36
(19
):1963
–72
.6.
Patel
SH
, Poisson
LM
, Brat
DJ
, Zhou
Y
, Cooper
L
, Snuderl
M
, . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project
. Clin Cancer Res
. 2017 Oct 15
;23
(20
):6078
–85
.7.
Broen
MPG
, Smits
M
, Wijnenga
MMJ
, Dubbink
HJ
, Anten
MHME
, Schijns
OEMG
, . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study
. Neuro Oncol
. 2018 Sep 3
;20
(10
):1393
–9
.8.
Lasocki
A
, Gaillard
F
, Gorelik
A
, Gonzales
M
. MRI features can predict 1p/19q status in intracranial gliomas
. AJNR Am J Neuroradiol
. 2018 Apr
;39
(4
):687
–92
.9.
Batchala
PP
, Muttikkal
TJE
, Donahue
JH
, Patrie
JT
, Schiff
D
, Fadul
CE
, . Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas
. AJNR Am J Neuroradiol
. 2019 Mar
;40
(3
):426
–32
.10.
Juratli
TA
, Tummala
SS
, Riedl
A
, Daubner
D
, Hennig
S
, Penson
T
, . Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups
. J Neurooncol
. 2019 Jan
;141
(2
):327
–35
.11.
Johnson
DR
, Kaufmann
TJ
, Patel
SH
, Chi
AS
, Snuderl
M
, Jain
R
. There is an exception to every rule-T2-FLAIR mismatch sign in gliomas
. Neuroradiology
. 2019 Feb
;61
(2
):225
–7
.12.
Yamasaki
F
, Kurisu
K
, Kajiwara
Y
, Watanabe
Y
, Takayasu
T
, Akiyama
Y
, . Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma
. Neuro Oncol
. 2011 Jul
;13
(7
):791
–801
.13.
Kuzan-Fischer
CM
, Souweidane
MM
. The intersect of neurosurgery with diffuse intrinsic pontine glioma
. J Neurosurg Pediatr
. 2019 Dec 1
;24
(6
):611
–21
.14.
Warren
KE
. Diffuse intrinsic pontine glioma: poised for progress
. Front Oncol
. 2012
;2
:205
.15.
Lassaletta
A
, Strother
D
, Laperriere
N
, Hukin
J
, Vanan
MI
, Goddard
K
, . Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience
. Pediatr Blood Cancer
. 2018 Jun
;65
(6
):e26988
.16.
Fontanilla
HP
, Pinnix
CC
, Ketonen
LM
, Woo
SY
, Vats
TS
, Rytting
ME
, . Palliative reirradiation for progressive diffuse intrinsic pontine glioma
. Am J Clin Oncol
. 2012 Feb
;35
(1
):51
–7
.17.
Khatua
S
, Zaky
W
. Diffuse intrinsic pontine glioma: time for therapeutic optimism
. CNS Oncol
. 2014
;3
(5
):337
–48
.18.
Massimino
M
, Biassoni
V
, Miceli
R
, Schiavello
E
, Warmuth-Metz
M
, Modena
P
, . Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood
. J Neurooncol
. 2014 Jun
;118
(2
):305
–12
.19.
Janssens
GO
, Gandola
L
, Bolle
S
, Mandeville
H
, Ramos-Albiac
M
, van Beek
K
, . Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group
. Eur J Cancer
. 2017 Mar
;73
:38
–47
.20.
Amsbaugh
MJ
, Mahajan
A
, Thall
PF
, McAleer
MF
, Paulino
AC
, Grosshans
D
, . A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma
. Int J Radiat Oncol Biol Phys
. 2019 May 1
;104
(1
):144
–8
.21.
Lu
VM
, Welby
JP
, Mahajan
A
, Laack
NN
, Daniels
DJ
. Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis
. Childs Nerv Syst
. 2019 May
;35
(5
):739
–46
.22.
Schwartzentruber
J
, Korshunov
A
, Liu
XY
, Jones
DT
, Pfaff
E
, Jacob
K
, . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
. Nature
. 2012 Jan 29
;482
(7384
):226
–31
.23.
Wu
G
, Broniscer
A
, McEachron
TA
, Lu
C
, Paugh
BS
, Becksfort
J
, . Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
. Nat Genet
. 2012 Jan 29
;44
(3
):251
–3
.24.
Castel
D
, Philippe
C
, Calmon
R
, Le Dret
L
, Truffaux
N
, Boddaert
N
, . Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
. Acta Neuropathol
. 2015 Dec
;130
(6
):815
–27
.25.
Broniscer
A
, Laningham
FH
, Sanders
RP
, Kun
LE
, Ellison
DW
, Gajjar
A
. Young age may predict a better outcome for children with diffuse pontine glioma
. Cancer
. 2008 Aug 1
;113
(3
):566
–72
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
